Understanding the Trial Results
This clinical trial is exploring how a traditional treatment, called Rasayana Formulation (RF) along with Shigru Pallava eye drops, can help people with Primary Open-Angle Glaucoma (POAG). The goal is to see if these treatments can protect the eyes and lower eye pressure better than standard care alone.
What Worked?
- If the trial shows that RF and Shigru Pallava eye drops effectively protect the optic nerve and lower eye pressure, it could mean better care for patients with glaucoma.
What Didn’t Work?
- Since the trial is still ongoing, we do not yet know if these treatments will be effective or how they compare to standard care.
Real-World Opportunities
- Doctors can consider integrating RF and Shigru Pallava eye drops into treatment plans for patients with POAG if they prove effective.
- Hospitals can prepare to offer these treatments as part of a comprehensive glaucoma management strategy.
Measurable Outcomes
- Clinics should track changes in optic nerve function using visual field tests and retinal nerve fiber layer thickness.
- They should also measure intraocular pressure (IOP) in patients receiving these treatments.
AI Tools for Monitoring
- AI-based tools can help clinics analyze visual field data and track changes in optic nerve health over time, making it easier to spot trends in patient outcomes.
Step-by-Step Plan for Clinics
- Start by educating staff about the trial and its potential implications for treatment.
- Identify a small group of patients who might benefit from the new treatment and monitor their progress closely.
- Gather data on IOP and optic nerve function from these patients.
- Evaluate the results after a set period and decide whether to expand the use of RF and Shigru Pallava eye drops.
